The treatment of oligometastatic disease appears to offer a significant survival advantage compared with polymetastatic disease, regardless of treatment choice. HRQOL measures were found to improve in both groups, demonstrating a palliative benefit for all treated patients.
No takes yet. Share an insight, caveat, or question.
Barzilai et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: